Silica Nanorattle–Doxorubicin-Anchored Mesenchymal Stem Cells for Tumor-Tropic Therapy
Citations Over TimeTop 10% of 2011 papers
Abstract
Low targeting efficiency is one of the biggest limitations for nanoparticulate drug delivery system-based cancer therapy. In this study, an efficient approach for tumor-targeted drug delivery was developed with mesenchymal stem cells as the targeting vehicle and a silica nanorattle as the drug carrier. A silica nanorattle-doxorubicin drug delivery system was efficiently anchored to mesenchymal stem cells (MSCs) by specific antibody-antigen recognitions at the cytomembrane interface without any cell preconditioning. Up to 1500 nanoparticles were uploaded to each MSC cell with high cell viability and tumor-tropic ability. The intracellular retention time of the silica nanorattle was no less than 48 h, which is sufficient for cell-directed tumor-tropic delivery. In vivo experiments proved that the burdened MSCs can track down the U251 glioma tumor cells more efficiently and deliver doxorubicin with wider distribution and longer retention lifetime in tumor tissues compared with free DOX and silica nanorattle-encapsulated DOX. The increased and prolonged DOX intratumoral distribution further contributed to significantly enhanced tumor-cell apoptosis. This strategy has potential to be developed as a robust and generalizable method for targeted tumor therapy with high efficiency and low systematic toxicity.
Related Papers
- → LncRNA LINC01094 contributes to glioma progression by modulating miR-224-5p/CHSY1 axis(2021)19 cited
- → Mesenchymal stem cell therapy in treatment of erectile dysfunction: Autologous or allogeneic cell sources?(2014)32 cited
- → MiRNA-93 functions as an oncogene in glioma by directly targeting RBL2.(2018)25 cited
- → Expression and functional implications of USP17 in glioma(2016)13 cited
- A comparison study of synthesizing methods of thiolated doxorubicin(2014)